TrialHuman vaccines & immunotherapeutics2025
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.
Sabine Schnyder Ghamloush et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it